CTAD 2022

Cogstate Scientific Involvement, Meeting Opportunities, and Networking Reception.

Cogstate is honored to be a part of the program at the 2022 CTAD meeting in San Francisco. We look forward to an exciting event with the opportunity to gather with colleagues and discuss new results and developments in the next generation of Alzheimer’s disease treatments.

We invite those attending the conference to come to our scientific presentations, stop by our networking reception, and/or reach out to book a meeting with either our clinical trials or healthcare teams!

Book a Meeting

Representatives from our clinical trials and healthcare teams will both be in attendance and would like to meet with you during the event. Cogstate has arranged an exclusive business suite in the conference hotel. Please reach out to your Cogstate contacts or submit this form and our team will reach out to make arrangements.

Attend our Networking Reception

We invite you to join us for a networking reception at a historical 1920’s style “speakeasy” to enjoy libations and light hors d’oeuvres! Be sure to register in advance as space is limited, and to receive the “password” to share with security to enter the venue.

Wed, Nov 30 | 5:30-7:00 PM | Bourbon & Branch


Cogstate Scientific Presentations at CTAD

For 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and patients around the world, with particular emphasis and experience in Alzheimer’s Disease. We are pleased to be part of the CTAD program.

  • Symposium | Nov 30 @ 1:20 PM: Decentralization Approaches for Clinical Trials on Alzheimer’s Disease | Presentation 2: Effects of supervision on cognitive and functional assessment outcomes (Paul Maruff, Presenter)
  • Oral Communication | Dec 2 @ 2:05 PM: Preliminary evidence for reliability and validity of the Interpersonal Functioning and Daily Activities Questionnaire (IFDAQ) in the A4/LEARN pre-randomization sample (Chris Edgar, Presenter)
  • Poster: XanaMIA Phase 1b trial with Xanamem® achieves primary endpoints: results and strategic update (Paul Maruff, Co-Author)
  • Poster: Clinical Activity of the p38⍺ kinase inhibitor neflamapimod on verbal list learning may be tau pathology dependent in dementia with Lewy bodies (DLB) (Cogstate assessments utilized)


Cogstate Experts Involved in Presentations

Paul Maruff, PhD

Paul Maruff, PhD

Chief Innovation Officer

Professor Paul Maruff is one of the founders of Cogstate. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioural and cognitive dysfunction. Paul’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods.

Chris Edgar, PhD

Chris Edgar, PhD

Chief Science Officer

Dr. Edgar is an experienced leader in cognitive assessment and clinical endpoint strategy who provides expert guidance to Cogstate’s pharmaceutical customers throughout all stages of trial conduct, from study design and test selection through final analysis. Dr. Edgar is also a key advisor to Cogstate’s commercial and product teams for the development of new technologies.

View the full CTAD program here

How can we help you optimize the measurement of brain health?

Contact Our Team